• Nautilus Biotechnology Inc NAUT.OQ reported a quarterly adjusted loss of 13 cents​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of -15 cents. The mean expectation of five analysts for the quarter was for a loss of 15 cents per share. Wall Street expected results to range from -17 cents to -13 cents per share.

• Reported revenue was zero​; analysts expected zero.

• Nautilus Biotechnology Inc's reported EPS for the quarter was a loss of 13 cents​.

• The company reported a quarterly loss of $16.61 million.

• Nautilus Biotechnology Inc shares had fallen by 21.0% this quarter and lost 59.5% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 17.3% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy," 2 "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "hold"

• Wall Street's median 12-month price target for Nautilus Biotechnology Inc is $1.75

This summary was machine generated from LSEG data April 29 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)